Plasma cell leukemia (PCL) is a rare aggressive variant of plasma myeloma. The differential diagnosis PCL includes multiple myeloma (MM), other leukemias, and lymphomas with abnormal cells circulating in the peripheral blood. In addition, infectious or autoimmune diseases can cause reactive polyclonal plasmacytosis, which could confuse us occasionally. Sometimes, blastoid morphology confusion d...

Survival of patients with multiple myeloma has improved substantially because of availability of new therapies including autotransplants, immunomodulating drugs and proteasome-inhibitors. Second primary cancers have emerged as an important determinant of morbidity and mortality among cancer survivors. Even though there is an increased risk of new cancers of the lymphoreticular and haematopoetic...

Plasma cell leukemia (PCL) is a rare form of malignant plasma cell dyscrasia. It can occur as a primary form without prior evidence of multiple myeloma or as a secondary form which is a terminal event in multiple myeloma. It is characterised by a proliferation of plasma cells in blood and the bone marrow. The outcome of plasma cell leukemia is poor with conventional therapy. Here we illustrate ...

Primary plasma cell leukemia: a rare type of leukemia and plasma cell proliferation Plasma cell leukemia is defined by the presence of more than 20% plasma cells in the peripheral blood or a number of circulating plasma cells greater than 2G/L. The primary form: observed may be de novo, and may reveal a multiple myeloma until then unknown. This has similarities with multiple myeloma and has som...

Plasma cell leukemia (PCL) is a rare lymphoproliferative disorder characterized by monoclonal proliferation of plasma cells in marrow and peripheral blood. It defined blood count greater than 2 G/l or 20% white cells. There are two forms PCL: primary PCL (primary PCL-P), which occurs de novo diagnosed dissemination, secondary (secondary SPL), the result evolution multiple myeloma (MM). We repor...